RxDoctor Payments DataLook up a doctor →

Kristi Nord, MD

Neurology · Louisville, KYNPI 1790931301

Payments from drug & device makers

$217,247in general payments, 2019–2025

Across 439 payments — averaging $494.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$142K
  • EMD Serono, Inc.$70K
  • AbbVie$2K
  • Medtronic$1K
  • MDD US Operations, LLC$242
  • Sanofi$220
  • plus $3K from 45 others

What the payments were for

  • Consulting fees$14,9937%
  • Speaking & faculty fees$166,11976%
  • Travel & lodging$29,32813%
  • Food & beverage$6,5183%
  • Education$2880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$217,247 in reported general payments places this provider in the 90th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$189,931
Medicare patients
554
Services billed
9,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4654$889,423
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5026$453,753
Kesimpta PenOfatumumab18$162,108
RytaryCarbidopa/Levodopa22$24,878
NourianzIstradefylline12$22,530
Droxidopa11$20,613
AptiomEslicarbazepine Acetate15$17,558
Dalfampridine ErDalfampridine35$16,599
Ajovy SyringeFremanezumab-Vfrm15$10,709
Emgality PenGalcanezumab-Gnlm12$10,557
BriviactBrivaracetam11$7,993
Lamotrigine ErLamotrigine22$6,155
Memantine Hcl37$4,456
Pregabalin114$3,227
Rivastigmine16$2,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$44$453,75326 claims
Amneal Pharmaceuticals LLCRytary$111$24,87822 claims
Kyowa Kirin, Inc.Nourianz$29$22,53012 claims
Sunovion Pharmaceuticals Inc.Aptiom$43$17,55815 claims
UCB, Inc.Briviact$113$7,99311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 210 neurology providers in Kentucky.

Other neurology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →